Merck & Co., Inc. (LON:MRK)

Market Cap	165.31B
Revenue (ttm)	46.43B
Net Income (ttm)	11.97B
Shares Out	n/a
EPS (ttm)	4.73
PE Ratio	13.81
Forward PE	9.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,604
Average Volume	273,851
Open	51.00
Previous Close	51.00
Day's Range	50.50 - 52.00
52-Week Range	47.50 - 63.00
Beta	0.67
RSI	15.71
Earnings Date	Oct 30, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Specialty Retail
• Sector: Consumer Discretionary
• Founded: 1891
• Employees: 75,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD